Difference between revisions of "HAEM5:Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[unchecked revision][unchecked revision]
Line 5: Line 5:
 
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Author (4th Edition)
 
!Correlated Prior Author (4th Edition)
 +
!Content Status (4th Edition)(Pending or Complete)
 
!Date of Last Editor Review (4th Edition)
 
!Date of Last Editor Review (4th Edition)
 
!Notes (4th Edition)
 
!Notes (4th Edition)
Line 13: Line 14:
 
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 26: Line 28:
 
|-
 
|-
 
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
 
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
 +
|NEW DISEASE
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
|
 
|
 
 
|-
 
|-
 
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
 
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
 +
|NEW DISEASE
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
|
 
|
 
 
|-
 
|-
 
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
 
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 +
|
 
|Date page was created
 
|Date page was created
 
|
 
|
Line 46: Line 51:
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 +
|
 
|Date page was created
 
|Date page was created
 
|
 
|
Line 52: Line 58:
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chelsea D. Kramish; Daynna J.Wolff
 
|Chelsea D. Kramish; Daynna J.Wolff
 +
|
 
|
 
|
 
|
 
|
Line 58: Line 65:
 
|Polycythemia Vera (PV)
 
|Polycythemia Vera (PV)
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
+
|Essential thrombocythaemia||Disease|| || || || || ||FQR|| ||
 
|Essential Thrombocythemia (ET)
 
|Essential Thrombocythemia (ET)
 +
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
 
|
 
|
 
|
 
|
Line 68: Line 77:
 
|-
 
|-
 
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| ||
 
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 74: Line 84:
 
|-
 
|-
 
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR|| ||
 
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 80: Line 91:
 
|-
 
|-
 
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
 
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 86: Line 98:
 
|-
 
|-
 
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
 
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 92: Line 105:
 
|-
 
|-
 
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
 
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 98: Line 112:
 
|-
 
|-
 
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
 
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 104: Line 119:
 
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 110: Line 126:
 
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 116: Line 133:
 
|-
 
|-
 
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 122: Line 140:
 
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 128: Line 147:
 
|-
 
|-
 
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 134: Line 154:
 
|-
 
|-
 
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 140: Line 161:
 
|-
 
|-
 
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 146: Line 168:
 
|-
 
|-
 
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 152: Line 175:
 
|-
 
|-
 
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 158: Line 182:
 
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 164: Line 189:
 
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 170: Line 196:
 
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 176: Line 203:
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 182: Line 210:
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 188: Line 217:
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 194: Line 224:
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 200: Line 231:
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 206: Line 238:
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 212: Line 245:
 
|-
 
|-
 
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 225: Line 259:
 
|
 
|
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 +
|
 
|
 
|
 
|
 
|
Line 240: Line 275:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 255: Line 291:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 270: Line 307:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 285: Line 323:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 300: Line 339:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 315: Line 355:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 330: Line 371:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 345: Line 387:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 360: Line 403:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 375: Line 419:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 390: Line 435:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 405: Line 451:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 420: Line 467:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 435: Line 483:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 450: Line 499:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 465: Line 515:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 480: Line 531:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 495: Line 547:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 510: Line 563:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 525: Line 579:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 540: Line 595:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 555: Line 611:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 570: Line 627:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 585: Line 643:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 600: Line 659:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 615: Line 675:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 630: Line 691:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 645: Line 707:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 660: Line 723:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 675: Line 739:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 690: Line 755:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 705: Line 771:
 
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 717: Line 784:
 
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 737: Line 805:
 
|
 
|
 
|Greg Corboy (GC)
 
|Greg Corboy (GC)
 +
|
 
|
 
|
 
|
 
|
Line 752: Line 821:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 767: Line 837:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 782: Line 853:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 797: Line 869:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 812: Line 885:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 827: Line 901:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 842: Line 917:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 857: Line 933:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 872: Line 949:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 887: Line 965:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 899: Line 978:
 
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 919: Line 999:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 934: Line 1,015:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 949: Line 1,031:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 964: Line 1,047:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 979: Line 1,063:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 994: Line 1,079:
 
|
 
|
 
|Holli Drendel (HD)
 
|Holli Drendel (HD)
 +
|
 
|
 
|
 
|
 
|
Line 1,009: Line 1,095:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,024: Line 1,111:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,039: Line 1,127:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,054: Line 1,143:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,069: Line 1,159:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,084: Line 1,175:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,099: Line 1,191:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,114: Line 1,207:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,129: Line 1,223:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,144: Line 1,239:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,159: Line 1,255:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,174: Line 1,271:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,189: Line 1,287:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,198: Line 1,297:
 
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
 
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,204: Line 1,304:
 
|-
 
|-
 
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
 
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,210: Line 1,311:
 
|-
 
|-
 
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,216: Line 1,318:
 
|-
 
|-
 
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,222: Line 1,325:
 
|-
 
|-
 
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,235: Line 1,339:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,250: Line 1,355:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,265: Line 1,371:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,280: Line 1,387:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,295: Line 1,403:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,310: Line 1,419:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,325: Line 1,435:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,340: Line 1,451:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,355: Line 1,467:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,370: Line 1,483:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,385: Line 1,499:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,400: Line 1,515:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,415: Line 1,531:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,430: Line 1,547:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,445: Line 1,563:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,453: Line 1,572:
 
|-
 
|-
 
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,459: Line 1,579:
 
|-
 
|-
 
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,465: Line 1,586:
 
|-
 
|-
 
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,471: Line 1,593:
 
|-
 
|-
 
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
 
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,477: Line 1,600:
 
|-
 
|-
 
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
 
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,483: Line 1,607:
 
|-
 
|-
 
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
 
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,489: Line 1,614:
 
|-
 
|-
 
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
 
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,495: Line 1,621:
 
|-
 
|-
 
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,501: Line 1,628:
 
|-
 
|-
 
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,507: Line 1,635:
 
|-
 
|-
 
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,513: Line 1,642:
 
|-
 
|-
 
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,519: Line 1,649:
 
|-
 
|-
 
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
 
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,525: Line 1,656:
 
|-
 
|-
 
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,531: Line 1,663:
 
|-
 
|-
 
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
 
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,537: Line 1,670:
 
|-
 
|-
 
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,543: Line 1,677:
 
|-
 
|-
 
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,549: Line 1,684:
 
|-
 
|-
 
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
 
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,555: Line 1,691:
 
|-
 
|-
 
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
 
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,561: Line 1,698:
 
|-
 
|-
 
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
 
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,567: Line 1,705:
 
|-
 
|-
 
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
 
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,573: Line 1,712:
 
|-
 
|-
 
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,579: Line 1,719:
 
|-
 
|-
 
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
 
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,585: Line 1,726:
 
|-
 
|-
 
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
 
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,591: Line 1,733:
 
|-
 
|-
 
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
 
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,597: Line 1,740:
 
|-
 
|-
 
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
 
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,603: Line 1,747:
 
|-
 
|-
 
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
 
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,609: Line 1,754:
 
|-
 
|-
 
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
 
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,615: Line 1,761:
 
|-
 
|-
 
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
 
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,621: Line 1,768:
 
|-
 
|-
 
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
 
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,634: Line 1,782:
 
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,642: Line 1,791:
 
|-
 
|-
 
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,648: Line 1,798:
 
|-
 
|-
 
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,655: Line 1,806:
 
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
 
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,662: Line 1,814:
 
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
 
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,669: Line 1,822:
 
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
 
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,676: Line 1,830:
 
|Mu heavy chain disease||Disease|| || || || || ||SG
 
|Mu heavy chain disease||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,683: Line 1,838:
 
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
 
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,690: Line 1,846:
 
|Alpha heavy chain disease||Disease|| || || || || ||SG
 
|Alpha heavy chain disease||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,697: Line 1,854:
 
|Plasmacytoma||Disease|| || || || || ||SG
 
|Plasmacytoma||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,704: Line 1,862:
 
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
 
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,711: Line 1,870:
 
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
 
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,721: Line 1,881:
 
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 1,735: Line 1,896:
 
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
 
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,741: Line 1,903:
 
|-
 
|-
 
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
 
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,747: Line 1,910:
 
|-
 
|-
 
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
 
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,753: Line 1,917:
 
|-
 
|-
 
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
 
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,766: Line 1,931:
 
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,781: Line 1,947:
 
|
 
|
 
|SK
 
|SK
 +
|
 
|
 
|
 
|
 
|
Line 1,789: Line 1,956:
 
|-
 
|-
 
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,795: Line 1,963:
 
|-
 
|-
 
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
 
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,801: Line 1,970:
 
|-
 
|-
 
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
 
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,807: Line 1,977:
 
|-
 
|-
 
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
 
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,813: Line 1,984:
 
|-
 
|-
 
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,819: Line 1,991:
 
|-
 
|-
 
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,825: Line 1,998:
 
|-
 
|-
 
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,831: Line 2,005:
 
|-
 
|-
 
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
 
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,837: Line 2,012:
 
|-
 
|-
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,843: Line 2,019:
 
|-
 
|-
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,849: Line 2,026:
 
|-
 
|-
 
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,855: Line 2,033:
 
|-
 
|-
 
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,861: Line 2,040:
 
|-
 
|-
 
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,867: Line 2,047:
 
|-
 
|-
 
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,873: Line 2,054:
 
|-
 
|-
 
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,879: Line 2,061:
 
|-
 
|-
 
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
 
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,885: Line 2,068:
 
|-
 
|-
 
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,891: Line 2,075:
 
|-
 
|-
 
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,897: Line 2,082:
 
|-
 
|-
 
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
 
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,903: Line 2,089:
 
|-
 
|-
 
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,909: Line 2,096:
 
|-
 
|-
 
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
 
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,915: Line 2,103:
 
|-
 
|-
 
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
 
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,921: Line 2,110:
 
|-
 
|-
 
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
 
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,927: Line 2,117:
 
|-
 
|-
 
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,933: Line 2,124:
 
|-
 
|-
 
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,939: Line 2,131:
 
|-
 
|-
 
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,945: Line 2,138:
 
|-
 
|-
 
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,951: Line 2,145:
 
|-
 
|-
 
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,957: Line 2,152:
 
|-
 
|-
 
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,963: Line 2,159:
 
|-
 
|-
 
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
 
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,969: Line 2,166:
 
|-
 
|-
 
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,975: Line 2,173:
 
|-
 
|-
 
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
 
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,981: Line 2,180:
 
|-
 
|-
 
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
 
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,991: Line 2,191:
 
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 2,011: Line 2,212:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,026: Line 2,228:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,041: Line 2,244:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,056: Line 2,260:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,071: Line 2,276:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,086: Line 2,292:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,101: Line 2,308:
 
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 2,113: Line 2,321:
 
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 2,126: Line 2,335:
 
|-
 
|-
 
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
 
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
Line 2,132: Line 2,342:
 
|-
 
|-
 
|Bloom syndrome||Disease|| || || || || ||NA|| ||
 
|Bloom syndrome||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
Line 2,138: Line 2,349:
 
|-
 
|-
 
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
 
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
Line 2,144: Line 2,356:
 
|-
 
|-
 
|RASopathies||Disease|| || || || || ||NA|| ||
 
|RASopathies||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|

Revision as of 20:35, 17 December 2023

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
Disease (5th Edition) Page Type Author (5th Edition) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Content Status (4th Edition)(Pending or Complete) Date of Last Editor Review (4th Edition) Notes (4th Edition)
CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)



Clonal haematopoiesis Disease Fabiola Quintero-Rivera (FQR) NEW DISEASE NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Clonal cytopenias of undetermined significance Disease FQR NEW DISEASE NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Chronic myeloid leukaemia Disease FQR Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) Date page was created
Chronic neutrophilic leukaemia Disease FQR Chronic Neutrophilic Leukemia (CNL) Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine **contributed equally Date page was created
Chronic eosinophilic leukaemia Disease FQR Chronic Eosinophilic Leukemia, Not Otherwise Specified Chelsea D. Kramish; Daynna J.Wolff
Polycythaemia vera Disease FQR Polycythemia Vera (PV) Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center
Essential thrombocythaemia Disease FQR Essential Thrombocythemia (ET) Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
Primary myelofibrosis Disease T. Niroshi Senaratne, UCLA FQR 8/4/2020 before submission
Juvenile myelomonocytic leukaemia Disease Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories FQR PENDING importing content and reference formatting; FQR has emailed SR several times, last 4/20/22
Myeloproliferative neoplasm, NOS Disease Thomas Lee, MD, PhD, University of California, Los Angeles FQR
Cutaneous mastocytosis Disease S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD FQR
Systemic mastocytosis Disease Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University FQR
Mast cell sarcoma Disease Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL FQR
Myelodysplastic neoplasm with low blasts and 5q deletion Disease FQR
Myelodysplastic neoplasm with low blasts and SF3B1 mutation Disease FQR
Myelodysplastic neoplasm with biallelic TP53 inactivation Disease FQR
Myelodysplastic neoplasm with low blasts Disease FQR
Myelodysplastic neoplasm, hypoplastic Disease FQR
Myelodysplastic neoplasm with increased blasts Disease Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. FQR
Childhood myelodysplastic neoplasm with low blasts Disease Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. FQR
Childhood myelodysplastic neoplasm with increased blasts Disease Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. FQR
Chronic myelomonocytic leukaemia Disease Linsheng Zhang, MD, PhD FQR
Myelodysplastic/myeloproliferative neoplasm with neutrophilia Disease Linsheng Zhang, MD, PhD FQR
Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis Disease Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine FQR
Myelodysplastic/myeloproliferative neoplasm, NOS Disease Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia FQR
Myeloid/lymphoid neoplasm with PDGFRA rearrangement Disease Jay Alden, DO FQR
Myeloid/lymphoid neoplasm with PDGFRB rearrangement Disease Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD FQR
Myeloid/lymphoid neoplasm with FGFR1 rearrangement Disease Yanna Ding, MD PhD FQR
Myeloid/lymphoid neoplasm with JAK2 rearrangement Disease Jessica Snider, M.D. and Daynna J. Wolff, PhD FQR
Myeloid/lymphoid neoplasm with FLT3 rearrangement Disease FQR
Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion Disease FQR
Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes Disease FQR
Acute promyelocytic leukaemia with PML::RARA fusion Disease Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. Jennelle Hodge (JH)/ Malini Sathanoori (MS)
Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion Disease Christine Bryke, MD
Beth Israel Deaconess Medical Center, Boston, MA
JH_MS
Acute myeloid leukaemia with CBFB::MYH11 fusion Disease Christine Bryke, MD
Beth Israel Deaconess Medical Center, Boston, MA
JH_MS
Acute myeloid leukaemia with DEK::NUP214 fusion Disease JH_MS
Acute myeloid leukaemia with RBM15::MRTFA fusion Disease Jennelle C. Hodge, PhD, FACMG JH_MS
Acute myeloid leukaemia with BCR::ABL1 fusion Disease Kay Weng Choy MBBS, Monash Medical Centre JH_MS
Acute myeloid leukaemia with KMT2A rearrangement Disease Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. JH_MS
Acute myeloid leukaemia with MECOM rearrangement Disease JH_MS
Acute myeloid leukaemia with NUP98 rearrangement Disease JH_MS
Acute myeloid leukaemia with NPM1 mutation Disease Xinjie Xu, PhD, FACMG JH_MS
Acute myeloid leukaemia with CEBPA mutation Disease Paul Defazio, MSc, Monash Health JH_MS
Acute myeloid leukaemia, myelodysplasia-related Disease Fei Yang, MD, FACMG
Oregon Health & Science University, Portland, OR
JH_MS
Acute myeloid leukaemia with other defined genetic alterations Disease JH_MS
Acute myeloid leukaemia with minimal differentiation Disease Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine JH_MS
Acute myeloid leukaemia without maturation Disease Jennelle C. Hodge, PhD, FACMG JH_MS
Acute myeloid leukaemia with maturation Disease Jennelle C. Hodge, PhD, FACMG JH_MS
Acute basophilic leukaemia Disease Ashwini Yenamandra PhD FACMG JH_MS
Acute myelomonocytic leukaemia Disease Fei Yang, MD, FACMG
Oregon Health & Science University, Portland, OR
JH_MS
Acute monocytic leukaemia Disease Fei Yang, MD, FACMG
Oregon Health & Science University, Portland, OR
JH_MS
Acute erythroid leukaemia Disease Ashwini Yenamandra PhD FACMG JH_MS
Acute megakaryoblastic leukaemia Disease Fei Yang, MD, FACMG
Oregon Health & Science University, Portland, OR
JH_MS
Myeloid sarcoma Disease Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine JH_MS
Myeloid neoplasm post cytotoxic therapy Disease Shawn A. Silver, DO, Shashi Shetty, Ph.D. JH_MS
Myeloid neoplasms associated with germline predisposition Disease JH_MS
Myeloid proliferations associated with Down syndrome Disease Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO JH_MS
Mixed-phenotype acute leukaemia with BCR::ABL1 fusion Disease Tracy Tucker, PhD, FCCMG JH_MS
Mixed-phenotype acute leukaemia with KMT2A rearrangement Disease Tracy Tucker, PhD, FCCMG JH_MS
Acute leukaemia of ambiguous lineage with other defined genetic alterations Disease JH_MS
Mixed-phenotype acute leukaemia, B/myeloid Disease Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD JH_MS
Mixed-phenotype acute leukaemia, T/myeloid Disease Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine JH_MS
Mixed-phenotype acute leukaemia, rare types Disease Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina JH_MS
Acute leukaemia of ambiguous lineage, NOS Disease JH_MS
Acute undifferentiated leukaemia Disease Amelia Nakanishi, MD and Shashi Shetty, PhD JH_MS
CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)



Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm Disease Greg Corboy (GC)
Blastic plasmacytoid dendritic cell neoplasm Disease Hao Liu, MD and Daynna J. Wolff, PhD GC
Langerhans cell histiocytosis Disease Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland GC
Langerhans cell sarcoma Disease Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland GC
Indeterminate dendritic cell tumour Disease GC
Interdigitating dendritic cell sarcoma Disease GC
Juvenile xanthogranuloma Disease GC
Erdheim-Chester disease Disease GC
Rosai-Dorfman Disease Disease GC
ALK-positive histiocytosis Disease GC
Histiocytic sarcoma Disease Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic GC
CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)



Reactive B-cell rich lymphoid proliferations that can mimic lymphoma Disease GC
IgG4-related disease Disease GC
Unicentric Castleman disease Disease GC
Idiopathic multicentric Castleman disease Disease GC
KSHV/HHV8-associated multicentric Castleman disease Disease Sudha Arumugam, MD GC
B-lymphoblastic leukaemia/lymphoma Disease Holli Drendel (HD)
B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy Disease Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG HD
B-lymphoblastic leukaemia/lymphoma with hypodiploidy Disease Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG HD
B-lymphoblastic leukaemia/lymphoma with iAMP21 Disease Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte HD
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion Disease Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG HD
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features Disease Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine HD
B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement Disease Yassmine Akkari Nicolas Millan HD
B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion Disease Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma HD
B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features Disease HD
B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion Disease Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO HD
B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion Disease Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO HD
B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion Disease HD
B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations Disease HD
B-lymphoblastic leukaemia/lymphoma, NOS Disease HD
Monoclonal B-cell lymphocytosis Disease Shivani Golem (SG)
Chronic lymphocytic leukaemia/small lymphocytic lymphoma Disease Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD SG
Hairy cell leukaemia Disease *Snehal Patel, MD, PhD SG
Splenic marginal zone lymphoma Disease *Snehal Patel, MD, PhD SG
Splenic diffuse red pulp small B-cell lymphoma Disease *Snehal Patel, MD, PhD SG
Splenic B-cell lymphoma/leukaemia with prominent nucleoli Disease *Snehal Patel, MD, PhD SG
Lymphoplasmacytic lymphoma Disease Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) SG
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue Disease SG
Primary cutaneous marginal zone lymphoma Disease SG
Nodal marginal zone lymphoma Disease Andrew Ly, DO and Shivani Golem, PhD, FACMG SG
Paediatric nodal marginal zone lymphoma Disease * Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD SG
In situ follicular B-cell neoplasm Disease Rachel D. Burnside, PhD, MBA, FACMGG SG
Follicular lymphoma Disease Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida SG
Paediatric-type follicular lymphoma Disease *Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG SG
Duodenal-type follicular lymphoma Disease SG
Primary cutaneous follicle centre lymphoma Disease Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG SG
In situ mantle cell neoplasm Disease Rina Kansal, MD; Versiti Blood Center of Wisconsin SG
Mantle cell lymphoma Disease * Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas SG
Leukaemic non-nodal mantle cell lymphoma Disease
SG
Transformations of indolent B-cell lymphomas Disease SG
Diffuse large B-cell lymphoma, NOS Disease Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center GC
T-cell/histiocyte-rich large B-cell lymphoma Disease GC
Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements Disease Kate Berry, MBBS, BBus (Hons), Pathology Queensland GC
ALK-positive large B-cell lymphoma Disease Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) GC
Large B-cell lymphoma with IRF4 rearrangement Disease *Afia Hasnain, MBBS, PhD GC
High grade B-cell lymphoma with 11q aberrations Disease Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina GC
Lymphomatoid granulomatosis Disease GC
EBV-positive diffuse large B-cell lymphoma Disease GC
Diffuse large B-cell lymphoma associated with chronic inflammation Disease GC
Fibrin-associated large B-cell lymphoma Disease GC
Fluid overload-associated large B-cell lymphoma Disease GC
Plasmablastic lymphoma Disease Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) GC
Primary large B-cell lymphoma of immune-privileged sites Disease Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center GC
Primary cutaneous diffuse large B-cell lymphoma, leg type Disease GC
Intravascular large B-cell lymphoma Disease Kate Berry, MBBS, BBus (Hons), Pathology Queensland GC
Primary mediastinal large B-cell lymphoma Disease GC
Mediastinal grey zone lymphoma Disease GC
High-grade B-cell lymphoma, NOS Disease Aiko Otsubo, PhD, Indiana University GC
Burkitt lymphoma Disease Becky Leung, MBBS (Hons), BSc, Pathology Queensland GC
Primary effusion lymphoma Disease GC
KSHV/HHV8-positive diffuse large B-cell lymphoma Disease GC
KSHV/HHV8-positive germinotropic lymphoproliferative disorder Disease GC
Hyperplasias arising in immune deficiency/dysregulation Disease GC
Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation Disease Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI) GC
EBV-positive mucocutaneous ulcer Disease GC
Lymphomas arising in immune deficiency / dysregulation Disease GC
Inborn error of immunity-associated lymphoid proliferations and lymphomas Disease GC
Classic Hodgkin lymphoma Disease Patricia V. Hernandez, M.D., Washington University School of Medicine GC
Nodular lymphocyte predominant Hodgkin lymphoma Disease GC
Cold agglutinin disease Disease SG
IgM monoclonal gammopathy of undetermined significance Disease SG
Non-IgM monoclonal gammopathy of undetermined significance Disease SG
Monoclonal gammopathy of renal significance Disease SG
Immunoglobulin-related (AL) amyloidosis Disease Heather E. Williams, PhD, MS, PgD, ErCLG SG
Monoclonal immunoglobulin deposition disease Disease Chen Yang, MD, PhD, University of Michigan SG
Mu heavy chain disease Disease SG
Gamma heavy chain disease Disease Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA SG
Alpha heavy chain disease Disease SG
Plasmacytoma Disease SG
Plasma cell myeloma / multiple myeloma Disease *Huan Mo, MD, MS *Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas SG
Plasma cell neoplasms with associated paraneoplastic syndrome Disease Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD SG
CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)



Kikuchi-Fujimoto disease Disease Sumi Kitahara (SK)
Autoimmune lymphoproliferative syndrome Disease SK
Indolent T-lymphoblastic proliferation Disease SK
T-lymphoblastic leukaemia / lymphoma, NOS Disease HD
Early T-precursor lymphoblastic leukaemia / lymphoma Disease Fei Yang, MD, FACMG, Kaiser Permanente Northwest HD
T-prolymphocytic leukaemia Disease SK
T-large granular lymphocytic leukaemia Disease *Michelle Don, MD, MS SK
NK-large granular lymphocytic leukaemia Disease Michelle Don, MD SK
Adult T-cell leukaemia/lymphoma Disease Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center SK
Sezary syndrome Disease Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina SK
Aggressive NK-cell leukaemia Disease Shanelle De Lancy, MD, Shashirekha Shetty, PhD SK
Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder Disease SK
Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder Disease SK
Mycosis fungoides Disease Jane Scribner, MD and Daynna J. Wolff, PhD SK
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis Disease SK
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma Disease Theresa Spivey, MD, Shashirekha Shetty, PhD SK
Subcutaneous panniculitis-like T-cell lymphoma Disease SK
Primary cutaneous gamma/delta T-cell lymphoma Disease SK
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma Disease SK
Primary cutaneous peripheral T-cell lymphoma, NOS Disease SK
Indolent T-cell lymphoma of the gastrointestinal tract Disease Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD SK
Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract Disease SK
Enteropathy-associated T-cell lymphoma Disease *Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD SK
Monomorphic epitheliotropic intestinal T-cell lymphoma Disease Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD SK
Intestinal T-cell lymphoma, NOS Disease Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) SK
Hepatosplenic T-cell lymphoma Disease *Michelle Don, MD, MS SK
ALK-positive anaplastic large cell lymphoma Disease SK
ALK-negative anaplastic large cell lymphoma Disease Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA SK
Breast implant-associated anaplastic large cell lymphoma Disease Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center SK
Nodal TFH cell lymphoma, angioimmunoblastic-type Disease * Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG SK
Nodal TFH cell lymphoma, follicular-type Disease SK
Nodal TFH cell lymphoma, NOS Disease Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD SK
Peripheral T-cell lymphoma, NOS Disease SK
EBV-positive nodal T- and NK-cell lymphoma Disease SK
Extranodal NK/T-cell lymphoma Disease SK
Severe mosquito bite allergy Disease SK
Hydroa vacciniforme lymphoproliferative disorder Disease SK
Systemic chronic active EBV disease Disease SK
Systemic EBV-positive T-cell lymphoma of childhood Disease *Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA SK
CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)



Follicular dendritic cell sarcoma Disease Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG GC
EBV-positive inflammatory follicular dendritic cell sarcoma Disease GC
Fibroblastic reticular cell tumour Disease GC
Intranodal palisaded myofibroblastoma Disease GC
Littoral cell angioma Disease GC
Splenic hamartoma Disease GC
Sclerosing angiomatoid nodular transformation (SANT) of spleen Disease GC
CHAPTER 7 (GENETIC TUMOUR SYNDROMES)



Fanconi anaemia Disease NA
Bloom syndrome Disease NA
Ataxia-telangiectasia syndrome Disease NA
RASopathies Disease NA